The impact of COVID-19 and other factors on the usage status of the biologic drug therapies for rheumatoid arthritis: A study from Vietnam Hai-Binh Bui, Hong-Thinh Lai, Thanh-Lam Nguyen, Thuy-Duong Vu, Nhat-Le Bui, Van-Hung Nguyen, Thi-To-Chau Tran, Thi-Phuong-Thuy Nguyen, Thi-Ngoc-Lan Nguyen, Jaffar A. Al-Tawfiq, Dinh-Toi Chu

Baseline comorbidities in patients with rheumatoid arthritis who have been prescribed biological therapy: A case control study Pilar Espiño-Lorenzo, Sara Manrique-Arija, Inmaculada Ureña, Francisco Gabriel Jiménez-Núñez, María López-Lasanta, Carmen María Romero-Barco, María Angeles Belmonte-López, María Victoria Irigoyen, Antonio Fernández-Nebro

Effectiveness and safety of tocilizumab in monotherapy in biologic-naïve and non-naïve patients with rheumatoid arthritis in a real-world setting Sara Marsal Barril, Mª Auxiliadora Martin-Martinez, Francisco Javier Blanco-Garcia, Antonio Fernández-Nebro, Rosario García de Vicuña, Jesús Tornero-Molina, Fernando Sánchez-Alonso, Marta Novella-Navarro, Alejandro Escudero-Contreras, Juan José Alegre-Sancho, Ana Urruticoechea-Arana, Maria Sagrario Bustabad-Reyes, Pilar Trenor-Larraz, Trinidad Pérez-Sandoval, Maria Isabel Tevar-Sánchez, Jesús T. Sánchez-Costa, Enrique Raya-Álvarez